B-control	0	11	Observation
O	12	18	versus
O	19	23	late
O	24	38	reintroduction
O	39	41	of
B-intervention	42	51	letrozole
O	52	54	as
O	55	63	adjuvant
O	64	73	endocrine
O	74	81	therapy
O	82	85	for
O	86	93	hormone
O	94	102	receptor
O	102	103	-
O	103	111	positive
O	112	118	breast
O	119	125	cancer
O	126	127	(
O	127	134	ANZ0501
O	135	140	LATER
O	140	141	)
O	141	142	:
O	143	145	an
O	146	150	open
O	150	151	-
O	151	156	label
O	157	167	randomised
O	167	168	,
O	169	179	controlled
O	180	185	trial
O	185	186	.

O	187	194	Despite
O	195	198	the
O	199	212	effectiveness
O	213	215	of
O	216	224	adjuvant
O	225	234	endocrine
O	235	242	therapy
O	243	245	in
O	246	256	preventing
O	257	263	breast
O	264	270	cancer
O	271	281	recurrence
O	281	282	,
O	283	289	breast
O	290	296	cancer
O	297	303	events
O	304	312	continue
O	313	315	at
O	316	317	a
O	318	322	high
O	323	327	rate
O	328	331	for
O	332	334	at
O	335	340	least
O	341	343	10
O	344	349	years
O	350	355	after
O	356	366	completion
O	367	369	of
O	370	377	therapy
O	377	378	.

O	379	383	This
O	384	394	randomised
O	395	399	open
O	400	405	label
O	406	411	phase
O	412	415	III
O	416	421	trial
O	422	431	recruited
B-eligibility	432	446	postmenopausal
I-eligibility	447	452	women
O	453	457	from
O	458	460	29
B-location	461	471	Australian
O	472	475	and
B-location	476	479	New
I-location	480	487	Zealand
O	488	493	sites
O	493	494	,
B-eligibility	495	499	with
I-eligibility	500	507	hormone
I-eligibility	508	516	receptor
I-eligibility	516	517	-
I-eligibility	517	525	positive
I-eligibility	526	531	early
I-eligibility	532	538	breast
I-eligibility	539	545	cancer
I-eligibility	545	546	,
I-eligibility	547	550	who
I-eligibility	551	554	had
I-eligibility	555	564	completed
I-eligibility	565	566	≥
I-eligibility	566	567	4
I-eligibility	568	573	years
I-eligibility	574	576	of
I-eligibility	577	586	endocrine
I-eligibility	587	594	therapy
O	595	596	[
O	596	605	aromatase
O	606	615	inhibitor
O	616	617	(
O	617	619	AI
O	619	620	)
O	620	621	,
O	622	631	tamoxifen
O	631	632	,
O	633	640	ovarian
O	641	652	suppression
O	652	653	,
O	654	656	or
O	657	667	sequential
O	668	679	combination
O	679	680	]
O	681	682	≥
O	682	683	1
O	684	688	year
O	689	694	prior
O	694	695	,
O	696	698	to
O	699	703	oral
O	704	713	letrozole
O	714	715	2
O	715	716	.
O	716	717	5
O	718	720	mg
O	721	726	daily
O	727	730	for
O	731	732	5
O	733	738	years
O	738	739	,
O	740	742	or
B-control	743	754	observation
O	754	755	.

O	756	765	Treatment
O	766	776	allocation
O	777	780	was
O	781	783	by
O	784	791	central
O	792	804	computerised
O	805	818	randomisation
O	818	819	,
O	820	830	stratified
O	831	833	by
O	834	845	institution
O	845	846	,
O	847	855	axillary
O	856	860	node
O	861	867	status
O	868	871	and
O	872	877	prior
O	878	887	endocrine
O	888	895	therapy
O	895	896	.

O	897	900	The
O	901	908	primary
O	909	916	outcome
O	917	920	was
B-outcome-Measure	921	929	invasive
I-outcome-Measure	930	936	breast
I-outcome-Measure	937	943	cancer
I-outcome-Measure	944	950	events
O	951	952	(
O	952	955	new
O	956	964	invasive
O	965	972	primary
O	972	973	,
O	974	979	local
O	979	980	,
O	981	989	regional
O	990	992	or
O	993	1000	distant
O	1001	1011	recurrence
O	1011	1012	,
O	1013	1015	or
O	1016	1029	contralateral
O	1030	1036	breast
O	1037	1043	cancer
O	1043	1044	)
O	1044	1045	,
O	1046	1054	analysed
O	1055	1057	by
O	1058	1067	intention
O	1068	1070	to
O	1071	1076	treat
O	1076	1077	.

O	1078	1081	The
O	1082	1091	secondary
O	1092	1100	outcomes
O	1101	1105	were
B-outcome-Measure	1106	1113	disease
I-outcome-Measure	1113	1114	-
I-outcome-Measure	1114	1118	free
I-outcome-Measure	1119	1127	survival
I-outcome-Measure	1128	1129	(
I-outcome-Measure	1129	1132	DFS
I-outcome-Measure	1132	1133	)
O	1133	1134	,
B-outcome-Measure	1135	1142	overall
I-outcome-Measure	1143	1151	survival
O	1151	1152	,
O	1153	1156	and
B-outcome-Measure	1157	1163	safety
O	1163	1164	.

O	1165	1172	Between
O	1173	1175	16
O	1176	1179	May
O	1180	1184	2007
O	1185	1188	and
O	1189	1191	14
O	1192	1197	March
O	1198	1202	2012
O	1202	1203	,
B-intervention-participants	1204	1207	181
O	1208	1216	patients
O	1217	1221	were
O	1222	1232	randomised
O	1233	1235	to
O	1236	1245	letrozole
O	1246	1249	and
B-control-participants	1250	1253	179
O	1254	1256	to
O	1257	1268	observation
O	1269	1270	(
O	1270	1276	median
O	1277	1280	age
B-age	1281	1283	64
I-age	1283	1284	.
I-age	1284	1285	3
I-age	1286	1291	years
O	1291	1292	)
O	1292	1293	.

O	1294	1303	Endocrine
O	1304	1311	therapy
O	1312	1315	was
O	1316	1325	completed
O	1326	1328	at
O	1329	1330	a
O	1331	1337	median
O	1338	1340	of
O	1341	1342	2
O	1342	1343	.
O	1343	1344	6
O	1345	1350	years
O	1351	1357	before
O	1358	1371	randomisation
O	1371	1372	,
O	1373	1376	and
O	1377	1379	47
O	1379	1380	.
O	1380	1381	5
O	1381	1382	%
O	1383	1386	had
O	1387	1394	tumours
O	1395	1397	of
O	1398	1399	>
O	1399	1400	2
O	1401	1403	cm
O	1404	1407	and
O	1407	1408	/
O	1408	1410	or
O	1411	1415	node
O	1416	1424	positive
O	1424	1425	.

O	1426	1428	At
O	1429	1430	3
O	1430	1431	.
O	1431	1432	9
O	1433	1438	years
O	1439	1445	median
O	1446	1452	follow
O	1452	1453	-
O	1453	1455	up
O	1456	1457	(
O	1457	1470	interquartile
O	1471	1476	range
O	1477	1478	3
O	1478	1479	.
O	1479	1480	1
O	1480	1481	-
O	1481	1482	4
O	1482	1483	.
O	1483	1484	8
O	1484	1485	)
O	1485	1486	,
B-iv-bin-abs	1487	1488	2
O	1489	1497	patients
O	1498	1506	assigned
O	1507	1516	letrozole
O	1517	1518	(
B-iv-bin-percent	1518	1519	1
I-iv-bin-percent	1519	1520	.
I-iv-bin-percent	1520	1521	1
I-iv-bin-percent	1521	1522	%
O	1522	1523	)
O	1524	1527	and
B-cv-bin-abs	1528	1530	17
O	1531	1539	patients
O	1540	1548	assigned
O	1549	1560	observation
O	1561	1562	(
B-cv-bin-percent	1562	1563	9
I-cv-bin-percent	1563	1564	.
I-cv-bin-percent	1564	1565	5
I-cv-bin-percent	1565	1566	%
O	1566	1567	)
O	1568	1571	had
O	1572	1583	experienced
O	1584	1586	an
B-outcome	1587	1595	invasive
I-outcome	1596	1602	breast
I-outcome	1603	1609	cancer
I-outcome	1610	1615	event
O	1616	1617	(
O	1617	1627	difference
O	1628	1629	8
O	1629	1630	.
O	1630	1631	4
O	1631	1632	%
O	1632	1633	,
O	1634	1636	95
O	1636	1637	%
O	1638	1648	confidence
O	1649	1657	interval
O	1658	1659	3
O	1659	1660	.
O	1660	1661	8
O	1661	1662	%
O	1663	1665	to
O	1666	1668	13
O	1668	1669	.
O	1669	1670	0
O	1670	1671	%
O	1671	1672	,
O	1673	1676	log
O	1676	1677	-
O	1677	1681	rank
O	1682	1686	test
O	1687	1688	P
O	1689	1690	=
O	1691	1692	0
O	1692	1693	.
O	1693	1697	0004
O	1697	1698	)
O	1698	1699	.

B-cv-bin-abs	1700	1706	Twenty
I-cv-bin-abs	1706	1707	-
I-cv-bin-abs	1707	1711	four
O	1712	1720	patients
O	1721	1722	(
B-cv-bin-percent	1722	1724	13
I-cv-bin-percent	1724	1725	.
I-cv-bin-percent	1725	1726	4
I-cv-bin-percent	1726	1727	%
O	1727	1728	)
O	1729	1731	in
O	1732	1735	the
O	1736	1747	observation
O	1748	1751	and
B-iv-bin-abs	1752	1754	14
O	1755	1756	(
B-iv-bin-percent	1756	1757	7
I-iv-bin-percent	1757	1758	.
I-iv-bin-percent	1758	1759	7
I-iv-bin-percent	1759	1760	%
O	1760	1761	)
O	1762	1764	in
O	1765	1768	the
O	1769	1778	letrozole
O	1779	1782	arm
O	1783	1794	experienced
O	1795	1796	a
B-outcome	1797	1800	DFS
I-outcome	1801	1806	event
O	1807	1808	(
O	1808	1811	log
O	1811	1812	-
O	1812	1816	rank
O	1817	1818	P
O	1819	1820	=
O	1821	1822	0
O	1822	1823	.
O	1823	1826	067
O	1826	1827	)
O	1827	1828	.

B-outcome	1829	1836	Adverse
I-outcome	1837	1843	events
O	1844	1850	linked
O	1851	1853	to
O	1854	1863	oestrogen
O	1864	1873	depletion
O	1873	1874	,
O	1875	1878	but
O	1879	1882	not
O	1883	1890	serious
O	1891	1898	adverse
O	1899	1905	events
O	1905	1906	,
O	1907	1911	were
O	1912	1916	more
O	1917	1923	common
O	1924	1928	with
O	1929	1938	letrozole
O	1938	1939	.

O	1940	1945	These
O	1946	1953	results
O	1954	1960	should
O	1961	1963	be
O	1964	1974	considered
O	1975	1986	exploratory
O	1986	1987	,
O	1988	1991	but
O	1992	1996	lend
O	1997	2003	weight
O	2004	2006	to
O	2007	2015	emerging
O	2016	2020	data
O	2021	2031	supporting
O	2032	2038	longer
O	2039	2047	duration
O	2048	2057	endocrine
O	2058	2065	therapy
O	2066	2069	for
O	2070	2077	hormone
O	2078	2086	receptor
O	2086	2087	-
O	2087	2095	positive
O	2096	2102	breast
O	2103	2109	cancer
O	2109	2110	,
O	2111	2114	and
O	2115	2120	offer
O	2121	2128	insight
O	2129	2133	into
O	2134	2148	reintroduction
O	2149	2151	of
O	2152	2154	AI
O	2155	2162	therapy
O	2162	2163	.

O	2164	2174	Australian
O	2175	2178	New
O	2179	2186	Zealand
O	2187	2195	Clinical
O	2196	2202	Trials
O	2203	2211	Registry
O	2212	2213	(
O	2213	2216	www
O	2216	2217	.
O	2217	2223	anzctr
O	2223	2224	.
O	2224	2227	org
O	2227	2228	.
O	2228	2230	au
O	2230	2231	)
O	2231	2232	,
O	2233	2252	ACTRN12607000137493
O	2252	2253	.
